Mind Medicine (MindMed) Inc. (MNMD) Financial Analysis & Valuation | Quarter Chart
Mind Medicine (MindMed) Inc. (MNMD)
MNMDPrice: $17.21
Fair Value: 🔒
🔒score
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention de... more
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to... more
Description
Shares
| Market Cap | $1.30B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Robert Barrow |
| IPO Date | 2016-11-15 | CAGR | — |
| Employees | 74 | Website | www.mindmed.co |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MNMD chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.40B | P/E Ratio | -8.69 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 3652085.75 |
| P/CF Ratio | -5659352.8 | P/FCF Ratio | -5014965.39 |
| EPS | $-1.98 | EPS Growth 1Y | 2.96% |
| EPS Growth 3Y | -60.23% | EPS Growth 5Y | 46.31% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.86% | ROA | -0.71% |
| ROCE | -0.88% | Current Ratio | 3.3 |
| Quick Ratio | 3.3 | Cash Ratio | 0.31 |
| Debt/Equity | — | Interest Coverage | -65.11 |
| Altman Z Score | 2.76 | Piotroski Score | 2 |